French pharmaceutical company said drug could treat COVID-19 patients after promising test results

19 March 2020
592 Views

A leading French pharmaceutical company said it could potentially treat 300,000 COVID-19 patients with the anti-malarial drug Plaquenil after what it described as “promising” test results.

Sanofi said it was ready to offer France millions of doses of Plaquenil, a spokesperson for the laboratory told AFP, adding that the group was ready to work with French health authorities “to confirm these results.”

The study on 24 patients with coronavirus using Plaquenil, a hydroxychloroquine molecule, which has also been used for decades for the treatment of autoimmune diseases like lupus or rheumatoid arthritis.

Six days after the start of taking Plaquenil, the virus had disappeared in three-quarters of those treated, said Professor Didier Raoult, who is director of the Institut Hospitalo-Universitaire de Marseille.

The French government said the clinical trials were “promising” and would be extended to more patients.

source: arabnews.com

You may be interested

US: There will be costs if Russia acts against Ukraine
DEFENCE
shares14 views
DEFENCE
shares14 views

US: There will be costs if Russia acts against Ukraine

Panos - Apr 12, 2021

U.S Secretary of State Antony Blinken on Sunday said: “it would be a serious mistake” for China to strike at…

Kikilias: The plan is for vaccinations of healthy people in their 40s to begin in June
GREECE
shares11 views
GREECE
shares11 views

Kikilias: The plan is for vaccinations of healthy people in their 40s to begin in June

Panos - Apr 12, 2021

If everything goes according to plan and deliveries for the second quarter are made on time, vaccinations of healthy people…

Euro 2021 with fans in stadiums, UEFA decides
GREECE
shares24 views
GREECE
shares24 views

Euro 2021 with fans in stadiums, UEFA decides

Panos - Apr 12, 2021

The Euro 2021, which was postponed last year due to the coronavirus, will be held next summer with fans allowed…

Leave a Comment

Your email address will not be published.